Rx Patent Reform Gets Renewed Interest From GOP As Alternative To Price Negotiation
Executive Summary
A Republican congressman and witness discuss shortened IP protections while criticizing Nancy Pelosi's drug price negotiation plan.
You may also be interested in...
FDA Airs ‘Concerns’ Over IP Barriers
Senators press for sharing of FDA applications with PTO as Woodcock letter seeks collaboration on everything from PTAB to patent term extensions to ‘possible misuse of the patent system.’
US FDA’s Patent ‘Concerns’ Include Thickets, Product Hopping, And Evergreening
Senators press for sharing of FDA applications with PTO as Woodcock letter seeks collaboration on everything from PTAB to patent term extensions to ‘possible misuse of the patent system.’
Outgoing BIO CEO Focuses On Out-Of-Pocket Costs As Solution To Drug Pricing Woes
In interview with the Pink Sheet, Jim Greenwood also worries about President Trump promoting drug pricing policies that could hinder innovation.